UK Heart Med Recall: Potency Issue Found

Health professionals in the UK have been instructed to immediately stop supplying specific batches of clopidogrel oral solution. This recall, issued by the Medicines and Healthcare products Regulatory Agency (MHRA), is due to a formulation error identified by Xeal Pharma. The affected products contain less clopidogrel than stated on the label, with impacted batches containing approximately 76% of the required amount. All batches produced prior to this notification are subject to this Class 2 recall, affecting patients, pharmacies, and wholesalers.

Individuals currently taking this heart medication are urged by the MHRA not to stop their dosage without first consulting a healthcare professional. Suddenly ceasing clopidogrel can precipitate serious thrombotic events. Patients will be contacted by their GP, specialist, or pharmacist to arrange for a replacement prescription. Once an alternative medication is secured, patients should return the recalled product to their pharmacy. For any concerns, patients are encouraged to contact their healthcare provider directly while continuing to take their prescribed medicine until a substitute is provided.